Term,Overlap,P.value,Adjusted.P.value,Old.P.value,Old.Adjusted.P.value,Odds.Ratio,Combined.Score,Genes
Long-term potentiation,4/67,3.396718615367122e-7,4.7214388753603e-5,0,0,90.33560090702947,1345.5745932880905,PRKCB;RPS6KA1;CACNA1C;RAF1
Fc gamma R-mediated phagocytosis,4/97,1.5098738363947304e-6,8.170632630785139e-5,0,0,61.10291858678955,818.9920199027146,VASP;MARCKS;PRKCB;RAF1
Chemical carcinogenesis,5/239,1.7634458915363608e-6,8.170632630785139e-5,0,0,32.45890861275477,430.0234364387223,PRKCB;RPS6KA1;CACNA1C;ADRB2;RAF1
Oxytocin signaling pathway,4/154,9.51017838964625e-6,3.3047869904020716e-4,0,0,37.775238095238095,436.80066593956695,CDKN1A;PRKCB;CACNA1C;RAF1
cGMP-PKG signaling pathway,4/167,1.3095972569790566e-5,3.6406803744017775e-4,0,0,34.739702015775634,390.5856196264213,VASP;CACNA1C;ADRB2;RAF1
GnRH secretion,3/64,2.4640226795251963e-5,5.708319207566705e-4,0,0,65.31475409836065,693.0633606976623,PRKCB;CACNA1C;RAF1
Non-small cell lung cancer,3/72,3.511295954409851e-5,6.895827945410313e-4,0,0,57.71884057971015,592.0187007331773,CDKN1A;PRKCB;RAF1
Glioma,3/75,3.968821839085072e-5,6.895827945410313e-4,0,0,55.30555555555556,560.4917293042834,CDKN1A;PRKCB;RAF1
ErbB signaling pathway,3/85,5.77270311363056e-5,8.915619253273866e-4,0,0,48.53658536585366,473.70663862607273,CDKN1A;PRKCB;RAF1
GnRH signaling pathway,3/93,7.550237601954301e-5,0.001049483026671648,0,0,44.20444444444445,419.5596960451344,PRKCB;CACNA1C;RAF1
Progesterone-mediated oocyte maturation,3/100,9.371291441807692e-5,0.0011841904640102446,0,0,41,380.2862565875762,RPS6KA1;RAF1;AURKA
"Parathyroid hormone synthesis, secretion and action",3/106,1.1142962034774952e-4,0.001272126921226339,0,0,38.6,351.34173063651644,CDKN1A;PRKCB;RAF1
MAPK signaling pathway,4/294,1.1897589910749935e-4,0.001272126921226339,0,0,19.400985221674876,175.3187415530873,PRKCB;RPS6KA1;CACNA1C;RAF1
Serotonergic synapse,3/113,1.347042039591539e-4,0.001337420310737314,0,0,36.13090909090909,322.0141715616055,PRKCB;CACNA1C;RAF1
MicroRNAs in cancer,4/310,1.4590312594336244e-4,0.0013520356337418254,0,0,18.371615312791786,162.26853559374524,CDKN1A;MARCKS;PRKCB;RAF1
"Growth hormone synthesis, secretion and action",3/119,1.5700387890341518e-4,0.0013639711979734194,0,0,34.251724137931035,300.0190737316632,PRKCB;CACNA1C;RAF1
Vascular smooth muscle contraction,3/133,2.18057591126721e-4,0.0017829414803890715,0,0,30.54153846153846,257.48811663353064,PRKCB;CACNA1C;RAF1
Insulin signaling pathway,3/137,2.3795238151637097e-4,0.00183752116837642,0,0,29.623880597014924,247.16506979433777,PRKAR2B;PRKAR2A;RAF1
mTOR signaling pathway,3/154,3.355813903351471e-4,0.0024550428029781815,0,0,26.266225165562915,210.1205040481858,PRKCB;RPS6KA1;RAF1
Hepatitis B,3/162,3.892671636350549e-4,0.0027054067872636315,0,0,24.93459119496855,195.76757582179673,CDKN1A;PRKCB;RAF1
Hepatocellular carcinoma,3/168,4.329664873318467e-4,0.002865825797101271,0,0,24.02060606060606,186.0359963592753,CDKN1A;PRKCB;RAF1
Bladder cancer,2/41,6.144037622474869e-4,0.0038819146796545767,0,0,63.91987179487179,472.6783914538256,CDKN1A;RAF1
Focal adhesion,3/201,7.300181442418315e-4,0.004411848784765852,0,0,19.983838383838386,144.33209705817518,VASP;PRKCB;RAF1
Proteoglycans in cancer,3/205,7.729597242269839e-4,0.004476725069481282,0,0,19.584158415841586,140.3260493897079,CDKN1A;PRKCB;RAF1
Rap1 signaling pathway,3/210,8.288645143685381e-4,0.004608486699889071,0,0,19.106280193236714,135.56772933321614,VASP;PRKCB;RAF1
cAMP signaling pathway,3/216,8.992780652935855e-4,0.004807678887531091,0,0,18.56244131455399,130.19544620156347,CACNA1C;ADRB2;RAF1
Human cytomegalovirus infection,3/225,0.0010118670805575455,0.005209241636944401,0,0,17.8018018018018,122.76047861882788,CDKN1A;PRKCB;RAF1
Calcium signaling pathway,3/240,0.00121873006908223,0.00588298948176716,0,0,16.662447257383967,111.8041194813529,PRKCB;CACNA1C;ADRB2
Endometrial cancer,2/58,0.0012273862947571772,0.00588298948176716,0,0,44.47767857142857,298.12802327286596,CDKN1A;RAF1
VEGF signaling pathway,2/59,0.0012697762309429347,0.005883296536702265,0,0,43.69517543859649,291.39939300135444,PRKCB;RAF1
Long-term depression,2/60,0.0013128624367881993,0.005886705764953538,0,0,42.939655172413794,284.92803390338764,PRKCB;RAF1
Amphetamine addiction,2/69,0.0017317817196253697,0.0070799311478801875,0,0,37.15485074626866,236.2530013272004,PRKCB;CACNA1C
Renal cell carcinoma,2/69,0.0017317817196253697,0.0070799311478801875,0,0,37.15485074626866,236.2530013272004,CDKN1A;RAF1
Renin secretion,2/69,0.0017317817196253697,0.0070799311478801875,0,0,37.15485074626866,236.2530013272004,CACNA1C;ADRB2
Melanoma,2/72,0.0018837899979258688,0.007481337420334164,0,0,35.55714285714286,223.10221103497707,CDKN1A;RAF1
Chronic myeloid leukemia,2/76,0.0020960030142903557,0.007874173486117823,0,0,33.62837837837838,207.41052527927255,CDKN1A;RAF1
Pancreatic cancer,2/76,0.0020960030142903557,0.007874173486117823,0,0,33.62837837837838,207.41052527927255,CDKN1A;RAF1
B cell receptor signaling pathway,2/81,0.0023764924719155735,0.00869295930516486,0,0,31.492088607594937,190.2792816750188,PRKCB;RAF1
Colorectal cancer,2/86,0.0026737657475791204,0.009291335972837444,0,0,29.610119047619047,175.4182632174737,CDKN1A;RAF1
Insulin secretion,2/86,0.0026737657475791204,0.009291335972837444,0,0,29.610119047619047,175.4182632174737,PRKCB;CACNA1C
Gap junction,2/88,0.0027973432696242373,0.0094656614267690075,0,0,28.91860465116279,170.0149390044448,PRKCB;RAF1
GABAergic synapse,2/89,0.0028601279131244485,0.0094656614267690075,0,0,28.58477011494253,167.41782366085732,PRKCB;CACNA1C
Salivary secretion,2/93,0.0031178798401161494,0.01007872785525918,0,0,27.322802197802197,157.66901828082703,PRKCB;ADRB2
Circadian entrainment,2/97,0.003386160098682633,0.010217585240680204,0,0,26.167105263157893,148.84003110829175,PRKCB;CACNA1C
Prostate cancer,2/97,0.003386160098682633,0.010217585240680204,0,0,26.167105263157893,148.84003110829175,CDKN1A;RAF1
Aldosterone synthesis and secretion,2/98,0.003454866951884673,0.010217585240680204,0,0,25.893229166666668,146.76208059313473,PRKCB;CACNA1C
Choline metabolism in cancer,2/98,0.003454866951884673,0.010217585240680204,0,0,25.893229166666668,146.76208059313473,PRKCB;RAF1
Melanogenesis,2/101,0.0036648982381020144,0.010612934481170415,0,0,25.10479797979798,140.8116748697442,PRKCB;RAF1
Insulin resistance,2/108,0.0041776435065928345,0.011824640951169004,0,0,23.43867924528302,128.39727114514832,PRKCB;RPS6KA1
HIF-1 signaling pathway,2/109,0.004253467968046405,0.011824640951169004,0,0,23.21845794392523,126.77325951701552,CDKN1A;PRKCB
Cholinergic synapse,2/113,0.004563160265358056,0.012174764910622098,0,0,22.37725225225225,120.60756830597164,PRKCB;CACNA1C
Glutamatergic synapse,2/114,0.004642176548654469,0.012174764910622098,0,0,22.176339285714285,119.143978155454,PRKCB;CACNA1C
Leukocyte transendothelial migration,2/114,0.004642176548654469,0.012174764910622098,0,0,22.176339285714285,119.143978155454,VASP;PRKCB
Sphingolipid signaling pathway,2/119,0.005046763352945088,0.012754547382897588,0,0,21.2232905982906,112.25015718571794,PRKCB;RAF1
Neurotrophin signaling pathway,2/119,0.005046763352945088,0.012754547382897588,0,0,21.2232905982906,112.25015718571794,RPS6KA1;RAF1
Thyroid hormone signaling pathway,2/121,0.005213013881359714,0.012939445169803577,0,0,20.86449579831933,109.67624832265864,PRKCB;RAF1
Oocyte meiosis,2/129,0.00590303543685089,0.014298554755755716,0,0,19.54232283464567,100.29684030209523,RPS6KA1;AURKA
FoxO signaling pathway,2/131,0.006081753147875876,0.014298554755755716,0,0,19.237403100775193,98.15812364603616,CDKN1A;RAF1
Natural killer cell mediated cytotoxicity,2/131,0.006081753147875876,0.014298554755755716,0,0,19.237403100775193,98.15812364603616,PRKCB;RAF1
Dopaminergic synapse,2/132,0.006172038024067215,0.014298554755755716,0,0,19.088461538461537,97.11686557699232,PRKCB;CACNA1C
Breast cancer,2/147,0.007599635728990646,0.017161015072222674,0,0,17.10086206896552,83.44630647041649,CDKN1A;RAF1
Retrograde endocannabinoid signaling,2/148,0.007699649802744419,0.017161015072222674,0,0,16.982876712328768,82.64853547573618,PRKCB;CACNA1C
Gastric cancer,2/149,0.007800263092908612,0.017161015072222674,0,0,16.866496598639454,81.86319105464948,CDKN1A;RAF1
Adrenergic signaling in cardiomyocytes,2/150,0.007901474565627706,0.017161015072222674,0,0,16.75168918918919,81.09000040913159,CACNA1C;ADRB2
Pathways of neurodegeneration,3/475,0.008329325421513174,0.017633820574403443,0,0,8.266949152542374,39.581927746613026,PRKCB;CACNA1C;RAF1
Cushing syndrome,2/155,0.008416468504225307,0.017633820574403443,0,0,16.200163398692812,77.39733293925609,CDKN1A;CACNA1C
Cellular senescence,2/156,0.008521247395824046,0.017633820574403443,0,0,16.094155844155843,76.69175138060437,CDKN1A;RAF1
Hepatitis C,2/157,0.00862661725942039,0.017633820574403443,0,0,15.98951612903226,75.99661638491506,CDKN1A;RAF1
JAK-STAT signaling pathway,2/162,0.009162295275844844,0.01845737743974541,0,0,15.4859375,72.67021710271118,CDKN1A;RAF1
Influenza A,2/172,0.010277387162359146,0.02040795450811316,0,0,14.56764705882353,66.68790899550402,PRKCB;RAF1
Pathways in cancer,3/531,0.01128278123335316,0.022088825231494216,0,0,7.368939393939394,33.04584291145216,CDKN1A;PRKCB;RAF1
Neutrophil extracellular trap formation,2/189,0.0123044039540048,0.023754335411203708,0,0,13.231951871657754,58.19145194893299,PRKCB;RAF1
Chemokine signaling pathway,2/192,0.012678984355525788,0.024052551357384367,0,0,13.021052631578948,56.873476489999355,PRKCB;RAF1
Kaposi sarcoma-associated herpesvirus infection,2/193,0.012804955398895276,0.024052551357384367,0,0,12.952225130890051,56.44480034874298,CDKN1A;RAF1
Human immunodeficiency virus 1 infection,2/212,0.015302515802612084,0.028360662620841064,0,0,11.76904761904762,49.19153594031784,PRKCB;RAF1
Ras signaling pathway,2/232,0.018140201960317973,0.033177474637949976,0,0,10.734782608695651,43.04244950696947,PRKCB;RAF1
African trypanosomiasis,1/37,0.0327950148043916,0.05770262098494218,0,0,32.591503267973856,111.38077026649428,PRKCB
Aldosterone-regulated sodium reabsorption,1/37,0.0327950148043916,0.05770262098494218,0,0,32.591503267973856,111.38077026649428,PRKCB
Thyroid cancer,1/37,0.0327950148043916,0.05770262098494218,0,0,32.591503267973856,111.38077026649428,CDKN1A
Human papillomavirus infection,2/331,0.03508710698481592,0.06096384838611767,0,0,7.4669452887538,25.01368084854925,CDKN1A;RAF1
PI3K-Akt signaling pathway,2/354,0.03965632130974999,0.06805220570438579,0,0,6.970880681818182,22.49855166852595,CDKN1A;RAF1
Type II diabetes mellitus,1/46,0.04061718578452446,0.06885108322010854,0,0,26.061437908496732,83.48948444789488,CACNA1C
Carbohydrate digestion and absorption,1/47,0.0414826184608072,0.06947089115725544,0,0,25.493606138107417,81.1329113370927,PRKCB
Alzheimer disease,2/369,0.04275365242349016,0.07074711531982299,0,0,6.680858310626703,21.06007399810004,CACNA1C;RAF1
Endocrine and other factor-regulated calcium reabsorption,1/53,0.04665975146146969,0.07630241709581513,0,0,22.54524886877828,69.09833217880467,PRKCB
Regulation of lipolysis in adipocytes,1/55,0.048379585909741875,0.07819491210993164,0,0,21.70806100217865,65.7467122997584,ADRB2
Basal cell carcinoma,1/63,0.05522966630423428,0.08824050133665017,0,0,18.89943074003795,54.73757147758474,CDKN1A
Cortisol synthesis and secretion,1/65,0.0569348954637786,0.08993125533483211,0,0,18.30698529411765,52.46501611587855,CACNA1C
Acute myeloid leukemia,1/67,0.058637217599069806,0.09157947467719892,0,0,17.750445632798574,50.34710965358108,RAF1
Fc epsilon RI signaling pathway,1/68,0.05948728998273248,0.09187481452888684,0,0,17.484635645302898,49.34151245692923,RAF1
Central carbon metabolism in cancer,1/70,0.06118526031669336,0.0924429476523954,0,0,16.97612958226769,47.42874202866335,RAF1
Prolactin signaling pathway,1/70,0.06118526031669336,0.0924429476523954,0,0,16.97612958226769,47.42874202866335,RAF1
p53 signaling pathway,1/73,0.06372678840915502,0.09524756547174784,0,0,16.266339869281047,44.783677915691136,CDKN1A
Thyroid hormone synthesis,1/75,0.06541752897671287,0.09616132598303193,0,0,15.825119236883944,43.154546742931096,PRKCB
Gastric acid secretion,1/76,0.06626181755179136,0.09616132598303193,0,0,15.613333333333332,42.376795202067306,PRKCB
Arrhythmogenic right ventricular cardiomyopathy,1/77,0.06710538575794313,0.09616132598303193,0,0,15.407120743034056,41.62219761611141,CACNA1C
Leishmaniasis,1/77,0.06710538575794313,0.09616132598303193,0,0,15.407120743034056,41.62219761611141,PRKCB
Taste transduction,1/86,0.07466517827093744,0.10590265081286024,0,0,13.76955017301038,35.728422579909434,CACNA1C
Cardiac muscle contraction,1/87,0.07550157451990408,0.1060072611946128,0,0,13.60875512995896,35.15960381916263,CACNA1C
PD-L1 expression and PD-1 checkpoint pathway in cancer,1/89,0.07717222548711895,0.10726939342709534,0,0,13.29812834224599,34.06602362525984,RAF1
Hypertrophic cardiomyopathy,1/90,0.07800648136170299,0.1073554545472942,0,0,13.148050231328488,33.540194413490916,CACNA1C
Morphine addiction,1/91,0.07884002491200945,0.10743885747813052,0,0,13.001307189542484,33.02766894797317,PRKCB
Small cell lung cancer,1/92,0.07967285673748564,0.1075196804515583,0,0,12.857789269553976,32.527973699604026,CDKN1A
Dilated cardiomyopathy,1/96,0.08299707803951369,0.11092878699511924,0,0,12.313931888544891,30.64875924889407,CACNA1C
Phosphatidylinositol signaling system,1/97,0.08382635971666402,0.11097013333920284,0,0,12.185049019607844,30.20683114705019,PRKCB
Inflammatory mediator regulation of TRP channels,1/98,0.08465493309372914,0.11100977075498444,0,0,12.058823529411764,29.775308154544383,PRKCB
AGE-RAGE signaling pathway in diabetic complications,1/100,0.08630995715059277,0.11121431018508043,0,0,11.81402257872846,28.942114306609312,PRKCB
Amoebiasis,1/102,0.08796215478207874,0.11121431018508043,0,0,11.578916715200933,28.146593675405043,PRKCB
Pancreatic secretion,1/102,0.08796215478207874,0.11121431018508043,0,0,11.578916715200933,28.146593675405043,PRKCB
T cell receptor signaling pathway,1/104,0.08961153050884178,0.11121431018508043,0,0,11.352941176470589,27.38637392725137,RAF1
C-type lectin receptor signaling pathway,1/104,0.08961153050884178,0.11121431018508043,0,0,11.352941176470589,27.38637392725137,RAF1
NF-kappa B signaling pathway,1/104,0.08961153050884178,0.11121431018508043,0,0,11.352941176470589,27.38637392725137,PRKCB
Cell cycle,1/124,0.10595107803152952,0.12918596356475967,0,0,9.49736967957915,21.31948479946905,CDKN1A
Platelet activation,1/124,0.10595107803152952,0.12918596356475967,0,0,9.49736967957915,21.31948479946905,VASP
Relaxin signaling pathway,1/129,0.10999247141798286,0.13294742197477927,0,0,9.124080882352942,20.13997932609556,RAF1
Apelin signaling pathway,1/137,0.11642283357542343,0.1359896963612089,0,0,8.583910034602075,18.459926845841217,RAF1
Autophagy,1/137,0.11642283357542343,0.1359896963612089,0,0,8.583910034602075,18.459926845841217,RAF1
Yersinia infection,1/137,0.11642283357542343,0.1359896963612089,0,0,8.583910034602075,18.459926845841217,RPS6KA1
Estrogen signaling pathway,1/137,0.11642283357542343,0.1359896963612089,0,0,8.583910034602075,18.459926845841217,RAF1
Apoptosis,1/142,0.12041950100185368,0.13810764613480572,0,0,8.277430120984564,17.521447135021635,RAF1
Signaling pathways regulating pluripotency of stem cells,1/143,0.12121678293846258,0.13810764613480572,0,0,8.218724109362055,17.34294402575858,RAF1
Spinocerebellar ataxia,1/143,0.12121678293846258,0.13810764613480572,0,0,8.218724109362055,17.34294402575858,PRKCB
Phospholipase D signaling pathway,1/148,0.12519296508571937,0.14147822883670724,0,0,7.937174869947979,16.492647814827816,RAF1
Wnt signaling pathway,1/166,0.13936698781759904,0.15622589763424408,0,0,7.06488413547237,13.922375947326568,PRKCB
Tight junction,1/169,0.14170813378799807,0.15757944477225386,0,0,6.937675070028011,13.556118103313043,VASP
Tuberculosis,1/180,0.15024097938130543,0.16574203280953537,0,0,6.507722642129478,12.335484222996,RAF1
Axon guidance,1/182,0.1517837725378262,0.1661255463209279,0,0,6.435164120896977,12.132204106132908,RAF1
Alcoholism,1/186,0.15486142607713563,0.16816982988063947,0,0,6.294753577106518,11.741129142703194,RAF1
Transcriptional misregulation in cancer,1/192,0.15945813830373404,0.17181923429627155,0,0,6.095164767477672,11.190563106127478,CDKN1A
Epstein-Barr virus infection,1/202,0.16706689368968466,0.1767239481971105,0,0,5.788996195493123,10.358603938884777,CDKN1A
Viral carcinogenesis,1/203,0.16782418102171645,0.1767239481971105,0,0,5.760046592894583,10.280752282136833,CDKN1A
Diabetic cardiomyopathy,1/203,0.16782418102171645,0.1767239481971105,0,0,5.760046592894583,10.280752282136833,PRKCB
Regulation of actin cytoskeleton,1/218,0.17910574948230568,0.18656361644581929,0,0,5.357820547573868,9.214266558139537,RAF1
Human T-cell leukemia virus 1 infection,1/219,0.17985269499093368,0.18656361644581929,0,0,5.332973556395035,9.149340756756814,CDKN1A
Thermogenesis,1/232,0.1895047592338975,0.1936850112758217,0,0,5.029539088362617,8.36583928133549,RPS6KA1
Coronavirus disease,1/232,0.1895047592338975,0.1936850112758217,0,0,5.029539088362617,8.36583928133549,PRKCB
Salmonella infection,1/249,0.20196488328128645,0.20491327573794757,0,0,4.680740037950664,7.487599357967169,RAF1
Prion disease,1/273,0.21924797234281013,0.2208367257655841,0,0,4.262543252595155,6.468630594433781,CACNA1C
Neuroactive ligand-receptor interaction,1/341,0.2663172520343859,0.2663172520343859,0,0,3.3982698961937716,4.496138770522036,ADRB2
